Misagh Karimi
Overview
Explore the profile of Misagh Karimi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egelston C, Guo W, Yost S, Ge X, Lee J, Frankel P, et al.
Cancer Immunol Immunother
. 2023 Jun;
72(9):3013-3027.
PMID: 37294342
Currently there is a limited understanding for the optimal combination of immune checkpoint inhibitor and chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC). Here we evaluate the safety, efficacy,...
2.
Crook C, Yen L, Ta K, Karimi M, Nguyen D, Lee R, et al.
J Clin Med
. 2023 Feb;
12(3).
PMID: 36769875
Neuroendocrine tumors are a rare type of cancer found in hormone-producing cells throughout the body. Research on disease-specific patient education assessments in this population is lacking. We previously demonstrated the...
3.
Loaiza-Bonilla A, Benson 3rd A, Grothey A, Karimi M, Klempner S, Lin D, et al.
Oncologist
. 2021 Mar;
26(8):651-659.
PMID: 33650740
The use of genomic testing is rapidly emerging as an important clinical tool both for cancer diagnosis and for guiding treatment decisions in a wide range of malignancies, including gastrointestinal...
4.
Karimi M, Wang C, Bahadini B, Hajjar G, Fakih M
J Clin Med
. 2020 Jun;
9(6).
PMID: 32498251
Colorectal cancer (CRC) management continues to evolve. In metastatic CRC, several clinical and molecular biomarkers are now recommended to guide treatment decisions. Primary tumor location (right versus left) has been...
5.
Bosserman L, Rogers K, Willis C, Davidson D, Whitworth P, Karimi M, et al.
PLoS One
. 2015 May;
10(5):e0122609.
PMID: 26024531
Background: A drug-induced apoptosis assay has been developed to determine which chemotherapy drugs or regimens can produce higher cell killing in vitro. This study was done to determine if this...
6.
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, et al.
Cancer Res
. 2012 Aug;
72(16):3901-5.
PMID: 22865459
A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic...